A vial with a potential COVID-19 vaccine at Novavax labs (AFP / MANILA BULLETIN)
Results of the vaccine’s Phase 3 trial also showed an 86.3 percent efficacy against B.1.1.7 variant first reported in the UK.
Meanwhile, the vaccine was found to be 55.4 percent effective against the B.1.351 variant that was first traced to South Africa.
“Because of the encouraging results, numerous studies have been expanded to include adolescents (12-17 years old), pregnant women, as well as on its potential use as booster in combination with other COVID-19 vaccines, and for seasonal revaccination,” local distributor Fabreco Life Sciences Inc. said.
It added that Novavax has expanded its manufacturing capacity, with several partners including the Serum Institute of India (SII) to meet the global demand.
Vaccine czar Secretary Carlito Galvez on Monday told the Senate Committee of the Whole that the bulk of the COVID19 vaccines that will be made available in the Philippines will come from US pharmaceutical company Novavax.